About Influenza
Influenza is a contagious respiratory disease caused by influenza viruses. These viruses infect the nose, throat, and lungs causing mild to severe illness. The disease can be fatal in some cases. Elderly people, young children, and people with medical conditions including liver disorders, blood disorders, kidney disorders, chronic lung disease, asthma, and neurodevelopmental and neurological conditions are at a higher risk of getting infected. Influenza vaccines are administered for active immunization against influenza virus. This, in turn, confers protection against influenza disease. Vaccination of high-risk groups prevents unnecessary hospitalizations and premature deaths resulting due to influenza.
TechNavio's analysts forecast the Global Influenza market to grow at a CAGR of 8.10 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Influenza market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines and drugs administered to prevent and treat human infection caused by influenza virus.
TechNavio's report, the Global Influenza Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Influenza market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline plc
• Novartis
• Sanofi Pasteur
Other Prominent Vendors
• Abbott
• Baxter International
• bioCSL
• Crucell
• Mitsubishi Tanabe Pharma
• Protein Sciences
• Serum Institute of India
• Sinovac Biotech
• Zydus Cadila
Market Driver
• Increased Awareness about Influenza
• For a full, detailed list, view our report
Market Challenge
• Antigenic Drift of Influenza Virus
• For a full, detailed list, view our report
Market Trend
• Emergence of Quadrivalent Vaccines for H1N1 Influenza
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Introduction and Classification
06.1.1 Seasonal Influenza
06.1.2 Pandemic influenza
06.1.3 Zoonotic or variant influenza
06.2 Influenza Season
06.3 Geographical Distribution
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Type of Influenza Virus
08.1.1 Influenza Type A Viruses
08.1.2 Influenza Type B Viruses
08.1.3 Influenza Type C Viruses
09. Global H1N1 Vaccines Market 2013-2018
09.1 Market Share
09.2 Market Segmentation
09.3 Market Size and Forecast
09.4 Geographical Segmentation
10. Market Segmentation by Product Type
11. Global Influenza Drugs Market
11.1 Market Segmentation
11.1.1 M2 Protein Inhibitors
11.1.2 Neuraminidase Inhibitors
11.2 Market Size and Forecast
11.3 Key Approved Influenza Drugs
11.3.1 In the US
11.3.2 In the EU
12. Global Influenza Vaccines Market
12.1 Market Segmentation
12.2 Market Size and Forecast
12.3 WHO Recommendation
12.4 Key Approved Influenza Vaccines
12.4.1 In the US
12.4.2 In the EU
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.3 Other Prominent Vendors
22. Key Vendor Analysis
22.1 AstraZeneca
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Strategy
22.1.5 Revenue by Business Segmentation
22.1.6 Revenue Comparison 2011-2013
22.1.7 Sales Revenue by Geographical Segmentation
22.1.8 Key Developments
22.1.9 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Geographical Segmentation by Revenue
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.3 GlaxoSmithKline
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Pipeline Products
22.3.7 Business Strategy
22.3.8 Key Information
22.3.9 SWOT Analysis
22.4 Novartis
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.5 Sanofi Pasteur
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Strategy
22.5.4 Recent Developments
22.5.5 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Percentage of Influenza Positive Cases and Virus Subtypes for Week 32, 2014
Exhibit 3: Number of Specimens Tested Positive for Influenza by Subtype, Global
Exhibit 4: Number of Specimens Tested Positive for Influenza by Subtype in Northern Hemisphere
Exhibit 5: Number of Specimens Tested Positive for Influenza by Subtype in Southern Hemisphere
Exhibit 6: Global Influenza Market 2013-2018 (US$ million)
Exhibit 7: Global Influenza Market Segmentation by Type of Influenza Virus
Exhibit 8: Share of H1N1 Vaccines in Global Influenza Market 2013
Exhibit 9: Revenue Share of H1N1 Vaccines in Global Influenza Vaccines Market 2013
Exhibit 10: Global H1N1 Vaccines Market Segmentation by Route of Administration
Exhibit 11: Global H1N1 Vaccines Market 2013-2018 (US$ million)
Exhibit 12: Global H1N1 Vaccines Market by Geographical Segmentation 2013
Exhibit 13: Global Influenza Market Segmentation by Product Type
Exhibit 14: Global Influenza Market Segmentation by Product Type 2013
Exhibit 15: Global Influenza Market Segmentation by Product Type 2018
Exhibit 16: Global Influenza Market Segmentation by Application 2013-2018 (US$ million)
Exhibit 17: YoY Growth Rate of Global Influenza Market Segments 2013-2018
Exhibit 18: Global Influenza Market Segments 2013-2018
Exhibit 19: Global Influenza Drugs Market 2013-2018 (US$ million)
Exhibit 20: Global Influenza Vaccines Market Segmentation by Route of Administration
Exhibit 21: Global Influenza Vaccines Market 2013-2018 (US$ million)
Exhibit 22: Global Influenza Market by Geographical Segmentation 2013
Exhibit 23: Global Influenza Market Share Analysis 2013
Exhibit 24: Sanofi Pasteur's Influenza Vaccine Segmentation by Geography 2013
Exhibit 25: Sales of Tamiflu by Geography 2013
Exhibit 26: Sales of Fluarix/FluLaval by Geography 2013
Exhibit 27: Sales of FluMist/Fluenz by Geography 2013
Exhibit 28: AstraZeneca: Business Segmentation
Exhibit 29: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 30: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 31: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 32: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 33: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 34: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 35: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 36: GlaxoSmithKline: Business Segmentation 2013
Exhibit 37: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 38: GlaxoSmithKline: Sales by Geography 2013
Exhibit 39: GlaxoSmithKline: Pipeline Products 2013
Exhibit 40: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 41: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 42: Novartis AG: Sales by Geography 2013
